Pursuit or discontinuation of anti-PD1 after 2 years of treatment in long-term responder patients with non-small cell lung cancer.

Camille Ardin,Sarah Humez,Vincent Leroy, Alexandre Ampere,Soraya Bordier,Fabienne Escande,Amélie Turlotte,Luc Stoven, David Nunes,Alexis Cortot,Clément Gauvain

Therapeutic advances in medical oncology（2023）

引用 0|浏览1

暂无评分

摘要

The decision to continue ICI or not after 2 years of treatment depends mainly on the care center and does not seem to impact survival. Larger, randomized data sets are required to confirm this result.

查看译文

关键词

ICI treatment duration, long-term responders, nivolumab, non-small cell lung cancer, pembrolizumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要